

Peritoneal Dialysis with Solutions Containing Amino Acids Plus Glucose Promotes Protein Synthesis during Oral Feeding

Hoey Lan Tjiong,* Trinet Rietveld,* Josias L. Wattimena,* Jacobus W. van den Berg,* Devada Kahrman,* José van der Steen,* Wim C. Hop,[†] Roel Swart,* and Marien W. Fieren*

Departments of *Internal Medicine and [†]Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands

Inadequate food intake plays an important role in the development of malnutrition. Recently, an increased rate of protein anabolism was shown in fasting state in patients who were on automated peritoneal dialysis with combined amino acids (AA) and glucose (G) dialysate serving as a source of both proteins and calories. This study investigated the effects of such a dialysis procedure in the daytime in the fed state in patients who were on continuous ambulatory peritoneal dialysis (CAPD). A crossover study was performed in 12 CAPD patients to compare, at 7-d intervals, a mixture of AA (Nutrineal 1.1%) plus G (Physioneal 1.36 to 3.86%) versus G only as control dialysate. Whole-body protein turnover was studied by primed constant intravenous infusion of ¹³C-leucine during the 9-h dialysis. For meeting steady-state conditions during whole-body protein turnover, frequent exchanges with a mixture of AA plus G were done using an automated cyclor. Fed-state conditions were created by identical liquid hourly meals. Using AA plus G dialysate, as compared with the control, rates of protein synthesis increased significantly (2.02 ± 0.08 versus 1.94 ± 0.07 μmol leucine/kg per min [mean \pm SEM]; $P = 0.039$). Rates of protein breakdown and net protein balance did not differ significantly between AA plus G and G. In conclusion, dialysate that contains AA plus G also improves protein synthesis in fed CAPD patients. The use of such a mixture may contribute to long-term improvement of the nutritional status in malnourished CAPD patients with deficient food intake.

Clin J Am Soc Nephrol 2: 74–80, 2007. doi: 10.2215/CJN.01370406

Many patients who are on peritoneal dialysis (PD) develop protein-energy malnutrition (1,2). Inflammation, acidosis, insulin resistance, insufficient intake of proteins and calories as a result of anorexia, and peritoneal losses of proteins and amino acids (AA) contribute to protein-energy malnutrition (3–5). A strong association between malnutrition, inflammatory parameters, and cardiovascular mortality has been reported (6–10). However, it is not understood completely how these factors are related causally.

Dialysate that contains AA was introduced to compensate for low protein intake and protein losses (11–13). The use of AA-containing dialysate was shown to be most effective when intraperitoneal AA were supplied simultaneously with sufficient oral calories (14–18). However, anorexia in continuous ambulatory PD (CAPD) patients prevents adequate oral intake of protein and calories. Recently, we showed improved protein anabolism in fasting patients who were on PD with dialysate that contained AA plus glucose (G) (18).

The daily cycle of fasting and feeding plays a key role in whole-body protein homeostasis. In this study, we examined the metabolic effects of AA plus G (AAG) dialysis in PD patients to determine whether the AAG mixture could contribute

to protein anabolism in the fed state. This could be of clinical relevance especially when daily protein and calorie intake of CAPD patients is insufficient. Effects of AAG dialysate on protein metabolism were studied using whole-body protein turnover (WBPT). Because metabolic steady-state conditions are not achieved with a standard CAPD scheme, frequent dialysate exchanges were done using an automated cyclor. The dialysis took place during the day while the patients consumed liquid food hourly in identical portions. This was a random-order crossover study in 12 patients to compare AAG dialysate with G dialysate as a control at 1-wk intervals.

Materials and Methods

Patients

Twelve CAPD patients were recruited from the PD Unit of the Erasmus Medical Center. Inclusion criteria called for stable patients who were on PD for >3 mo and had a weekly Kt/V >1.7. Exclusion criteria were peritonitis, other infectious or inflammatory diseases in the previous 6 wk, malignancy, and life expectancy <6 mo. The study was approved by the Medical Ethics Committee, and written informed consent was obtained from all patients.

Study Design

The study was a single-center, open-label, randomized, crossover study of 2 d with 1-wk interval to compare a dialysis scheme using either dialysate that contained AAG (Nutrineal 1.1% plus Physioneal 1.36 to 3.86%; Baxter BV, Utrecht, The Netherlands) or a control scheme that contained G only (Physioneal 1.36 to 3.86%). Dialysis was performed during a 9-h period (Figure 1). The end point of the study was WBPT. Before the study, all patients had a dialysis scheme of four

Received April 26, 2006. Accepted August 30, 2006.

Published online ahead of print. Publication date available at www.cjasn.org.

Address correspondence to: Dr. Hoey Lan Tjiong, Department of Internal Medicine, Erasmus MC, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Phone: +31-10-4634610; Fax: +31-10-4635092; E-mail: h.tjiong@erasmusmc.nl




Figure 1. Schematic diagram of the study-day protocol. ■, portions of the liquid food, the first two portions given half-hourly and thereafter hourly; ▲, time points of blood sampling; △ time points of breath sampling.

exchanges of G-based dialysis fluid (Physioneal 1.36 to 3.86%) in the daytime and a nighttime dwell of Physioneal 1.36 to 3.86% or Extraneal (Baxter BV). The night before the study days, all patients underwent dialysis with Extraneal. Patients were randomly assigned by drawing one of 12 sealed envelopes to determine whether patients started with either AAG or G on the first study day. Six patients each were allocated to start with AAG dialysis and G dialysis. On the 2 study days, the patients stayed at the Department of Nephrology of the Erasmus MC. They came at 8:00 a.m. and left at the end of the study after inflow of their usual nightly dialysate. At the end of each study day, they continued their usual dialysis scheme. During the 2 study days, the patients consumed a liquid complete diet that was comparable in nitrogen and energy content to their habitual diet. In each patient, dietary counseling had been performed at least once per 6 mo as a standard practice in our department.

Subjective Global Assessment

Subjective global assessment (SGA) as described by Detsky *et al.* (19) is based on clinical parameters. Patients are classified according to their nutritional status into three groups: A, good nutritional status; B, moderate malnutrition; or C, severe malnutrition.

Dialysis Procedures

Six daytime exchanges were performed automatically using a cycler (HomeChoice; Baxter BV). The AAG dialysate was obtained by mixing one bag of 2.5 L of Nutrineal 1.1% (containing 27.5 g of AA), and four bags of 2.5 L of Physioneal 1.36 to 3.86% G. For G dialysis, five bags of 2.5 L of Physioneal 1.36 to 3.86% were infused. G concentrations were individualized depending on ultrafiltration targets. The composition of the AA 1.1% dialysis solution and the precise mixing procedures that were required to obtain metabolic steady-state conditions for WBPT studies were performed as described previously (18).

WBPT Studies

Rates of WBPT were determined with a primed continuous intravenous infusion of ^{13}C -leucine, which was carried out at the end of the 9-h dialysis period between 3:30 p.m. and 6:30 p.m. At approximately 8:20 a.m., two catheters were inserted into superficial veins on both arms, one for continuous infusion of the tracer solution, the other for repeated blood sampling. Baseline blood samples and expiratory breath samples were collected before starting the oral feeding at 8:20 a.m. The dialysis started at 9:30 a.m. (T_0). At 3:30 p.m., priming doses of L-[1- ^{13}C]leucine (3.8 $\mu\text{mol}/\text{kg}$) and of $\text{NaH}^{13}\text{CO}_3$ (1.7 $\mu\text{mol}/\text{kg}$) were given to label the leucine and CO_2 pools, followed by a continuous infusion of L-[1- ^{13}C]leucine (infusion rate 0.063 $\mu\text{mol}/\text{kg}$ per min) and continued for 180 min until the end of the dialysis period at 6:30 p.m. (T_{540}). For

measurement of plateau plasma keto-isocaproic acid (KIC) and CO_2 ^{13}C enrichment, blood and expired air samples were collected simultaneously at T_{480} , T_{510} , T_{525} , and T_{540} min (*i.e.*, at 120, 150, 165, and 180 min) after priming and starting the tracer infusion. Indirect calorimetry (Deltatrac metabolic monitor; Datex, Helsinki, Finland) was performed to measure CO_2 production. Patients were not allowed to eat except their liquid diet during the whole study day; however, noncaloric beverages were permitted.

Liquid Diet

A renal dietitian instructed the patients to keep a 4-d food diary. On the basis of these food records and a subsequent dietary interview, the appropriate calorie and protein content of the study diet was calculated. The prescribed study diet consisted of a combination of two commercially available complete liquid nutritional products (Nutridrink and Fortimel; Nutricia, Zoetermeer, The Netherlands). The total food volume was divided into 11 equal portions. The first two meal portions were given at half-hourly intervals, and the remaining nine portions were given at hourly interval thereafter (Figure 1).

Analytical Determination

Leucine carbon flux was calculated from the ^{13}C enrichment of KIC as described previously (18,20). In brief, the ^{13}C enrichment was determined by gas chromatography–mass spectrometry by measurement of the fragments 259 and 260 of natural- and ^{13}C -KIC, respectively. Oxidation of L-[1- ^{13}C]leucine was determined by measurement of breath CO_2 ^{13}C enrichment.

Blood Chemistries

Blood samples were taken before the first dialysate exchange (fasting state) and at the end of the study days. Insulin was measured by a chemiluminescent immunometric assay (Immulite 2000 Insulin; DPC, Los Angeles, CA). The other determinations were performed by routine laboratory procedures.

Calculations of WBPT

Metabolic leucine carbon flux was calculated as described previously (21). On the basis of the one-pool model at equilibrium, leucine carbon flux (Q) is equal to the sum of endogenous leucine appearance from protein breakdown (B) plus exogenous leucine appearance through oral intake (I_o) and *via* dialysate (I_d). At metabolic equilibrium, Q also is equal to the sum of leucine disappearance into body proteins (S) plus leucine oxidation (O). Thus, $Q = S + O = B + I_o + I_d$. Plasma KIC enrichment provides a better estimate of intracellular leucine enrichment than does plasma leucine enrichment because KIC is derived from intracellular leucine metabolism (20). Leucine flux in $\mu\text{mol}/\text{kg}$ per hr is calculated as $Q = \text{Inf} (E_i/E_{\text{plasma KIC}} - 1)$, where Inf is the leucine infusion rate ($\mu\text{mol}/\text{kg}$ per hr), E_i is the ^{13}C enrichment of the L-[1- ^{13}C]leucine infused, and E_{KIC} is the ^{13}C enrichment of plasma KIC as measured at isotopic equilibrium. Isotopic steady state (plateau plasma ^{13}C -KIC enrichment) was found between T_{480} and T_{540} min. Leucine oxidation (O ; $\mu\text{mol}/\text{kg}$ per hr) is calculated as $O = F^{13}\text{CO}_2 (1/E_{\text{KIC}} - 1/E_i) \times 100$, where $F^{13}\text{CO}_2$ (in $\mu\text{mol } ^{13}\text{C}/\text{kg}$ per hr) is the rate at which $^{13}\text{CO}_2$ is expired as calculated from CO_2 ^{13}C enrichment in expired air and from CO_2 production. Leucine absorption from dialysate (I_d) was calculated by subtracting the amount of leucine in spent dialysate from that in fresh dialysate. Loss of leucine (L_d) in G dialysate was included in the total rate of disappearance of leucine. Thus, during G dialysis, $Q = B + I_o = S + O + L_d$. During AAG dialysis, $Q = B + I_o + I_d = S + O$. A fraction of 0.25 of absorbed leucine was assumed for the retention in the splanchnic bed (22). This correction factor was ap-

plied for leucine both from diet and dialysate. A fraction of 0.32 was assumed for the oxidation of leucine taken up by the splanchnic region (22). Therefore, leucine fluxes and rates of whole-body protein synthesis and breakdown corrected for splanchnic uptake were calculated as follows: $Q_c = \text{measured flux} + (I_o + I_d) \times 0.25$, where Q_c is corrected flux. The corrected oxidation (O_c) = measured oxidation + $[(I_o + I_d) \times 0.25] \times 0.32$. The corrected protein synthesis = $Q_c - O_c$. The corrected breakdown $B_c = Q_c - (I_o + I_d)$.

Statistical Analyses

Data were analyzed using the statistical program SPSS, version 11.0, for Windows (SPSS Inc., Chicago, IL). Data are expressed as mean \pm SEM or indicated otherwise. The paired *t* test was used to compare differences between the two treatment regimens (AAG versus G dialysis). This comparison also was done in the subgroup of malnourished patients. The unpaired *t* test was used to compare differences regarding protein synthesis, protein breakdown, and net protein balance between the present fed state study and the previous published fasting state study. Differences were considered statistically significant when the two-sided *P* value was < 0.05 . Power calculations, based on our previous study (18), had led to 12 patients for this crossover study.

Results

The baseline characteristics of the 12 patients are shown on Table 1. Three patients (1, 3, and 5) were anuric, whereas most of the other patients had a substantial residual renal function. According to the SGA classification in this study, four of the 12 patients were moderately malnourished. None of the patients used prednisone. The study protocol was well tolerated by all patients. No complaints of nausea or other adverse reactions were reported during the AAG dialysis. None of the patients dropped out of the study.

WBPT

Essential conditions for measuring WBPT were met as shown in Figures 2 and 3, showing that isotopic steady state in plasma ^{13}C -KIC and exhaled breath $^{13}\text{CO}_2$ was reached within the time frame of sampling (T_{480} to T_{540}). There was a slight increase in

breath $^{13}\text{CO}_2$ enrichment on feeding with liquid food. However, a new steady state was reached before sampling for analytical purposes was started (Figure 3). In this study, we measured that net peritoneal absorption of leucine was $39.3 \pm 7.1\%$ of the supplied amount.

Protein turnover results in Table 2 show that the leucine flux with AAG mixture was increased compared with G dialysis (2.90 ± 0.13 versus 2.67 ± 0.11 μmol leucine/kg per min; mean difference 0.23 ± 0.05 μmol leucine/kg per min; $P = 0.001$). Leucine oxidation increased significantly with AAG dialysate compared with G dialysate (0.88 ± 0.06 versus 0.74 ± 0.06 μmol leucine/kg per min; mean difference 0.14 ± 0.02 μmol leucine/kg per min; $P < 0.001$). Protein synthesis increased significantly with the mixture (2.02 ± 0.08 versus 1.94 ± 0.07 μmol leucine/kg per min; mean difference 0.08 ± 0.04 μmol leucine/kg per min; $P = 0.039$). Overall, net protein balance was not significantly increased using AAG dialysate compared with G dialysate (mean difference 0.03 ± 0.03 μmol leucine/kg per min; $P = 0.347$). There also were no significant differences regarding protein breakdown ($P = 0.346$).

Within the subgroup of malnourished patients (Table 1, SGA classification B, $n = 4$), the net protein balance with AAG was significantly higher than with G dialysis (mean difference 0.13 ± 0.02 μmol leucine/kg per min; $P = 0.0063$). This difference was significantly higher (unpaired *t* test $P = 0.0058$) than the corresponding value in the group of eight well-nourished patients (difference -0.02 ± 0.03 μmol leucine/kg per min).

Protein and Energy Intake

Table 1 shows the average prestudy (*i.e.*, habitual) dietary protein and calorie intake estimates based on a dietary interview and 4-d food records. The proportion of dietary energy and protein varied between 107 and 157 kcal/gN (mean 141 kcal/gN). The liquid food contained on average 0.96 ± 0.2 g protein/kg per d and 22 ± 5.0 kcal/kg per d, which was consumed completely and was well tolerated in all patients.

Table 1. Baseline characteristics of the patients^a

Patient	Primary Diagnosis of Renal Disease	Time on PD (mo)	Gender	Age (yr)	BMI (wt/ht ²)	SGA	PET	Kt/V	nPNA (g/kg per d)	Protein (g/kg per d)	Energy (kcal/kg per d)
1	Unknown kidney disease	28	M	69	32.8	B	H	1.91	0.89	0.59	11.1
2	Chronic pyelonephritis	20	F	43	22.0	B	HA	2.73	0.97	0.75	16.7
3	IgA nephropathy	15	M	33	21.4	B	H	1.86	0.69	0.90	32.1
4	Unknown kidney disease	9	M	59	24.5	A	HA	2.64	1.37	1.14	19.4
5	Hypertensive nephropathy	72	F	62	28.6	A	HA	2.02	0.76	0.68	16.0
6	Membranous glomerulopathy	5	M	56	25.8	A	LA	3.10	0.89	0.73	17.8
7	Hypertensive nephropathy	4	M	70	23.7	B	HA	2.00	0.79	0.93	23.4
8	Chronic pyelonephritis	15	F	52	23.7	A	HA	2.68	1.27	1.38	26.4
9	Nephrolithiasis	9	M	35	32.6	A	H	2.46	1.15	1.01	26.6
10	Hypertensive nephropathy	6	M	63	25.5	A	HA	2.65	1.01	0.98	26.5
11	Hypertensive nephropathy	4	F	53	28.6	A	HA	2.61	0.73	1.27	25.8
12	Diabetic nephropathy	4	M	62	27.7	A	HA	2.21	0.56	0.90	19.8
	Mean	15.9		54.8	26.4			2.41	0.92	0.94	22.8
	SD	19.2		12.2	3.8			0.40	0.24	0.24	6.0

^aA, good nutritional status; B, moderate malnutrition; BMI, body mass index; H, high; HA, high average; LA, low average; nPNA, normalized protein equivalent of nitrogen appearance (PD Adequest 2.0 software; Baxter); PET, peritoneal equilibrium test; SGA, subjective global assessment.




Figure 2. Plateau ¹³C-ketoisocaproic acid (KIC) enrichment during whole-body protein turnover (WBPT) study. ¹³C-KIC values (mean ± SD) in 12 patients in moles percent excess (MPE). ▲, amino acids plus glucose (AAG) dialysis; △, glucose dialysis.




Figure 3. The course of the breath ¹³CO₂ levels during consumption of the liquid meals and during the WBPT study with AAG dialysate. Values (mean ± SD) in 12 patients are expressed in Atom % ¹³CO₂.

The proportion of dialysate energy and protein ranged from 124 to 243 kcal/gN (mean 161 kcal/gN).

Biochemical Parameters

As shown in Table 3, serum bicarbonate, creatinine, urea, G, and insulin concentrations did not show a statistically significant difference between AAG and G dialysis. Insulin levels significantly increased during both AAG and G dialysis as compared with fasting baseline conditions. During dialysis, serum creatinine decreased. Mean plasma leucine concentra-

tions were significantly increased with AAG compared with G dialysate ($P = 0.003$). The loss of leucine into dialysate during G dialysis was $0.65 \pm 0.11 \mu\text{mol/L}$. Protein loss and excretion of urea in dialysate did not differ with either type of dialysate.

Discussion

Recently, we reported that intraperitoneal administration of calories combined with AA to fasting automated peritoneal dialysis patients as part of their regular nightly dialysis scheme improved protein anabolism (18). In this study, we investigated whether AAG dialysate could serve as a useful extra supply of nutrients to CAPD patients in a fed state, considering that many of these patients have deficient intake of protein and calories as a result of anorexia. WBPT studies were carried out in fed-state CAPD patients in the daytime using a primed constant infusion of a stable isotope. Instead of manual changes of dialysis fluids, AAG solutions frequently were exchanged using an automated cyler to achieve the steady-state conditions that were required for the WBPT studies.

Administration of AAG dialysate increased both leucine flux and leucine oxidation significantly compared with G dialysate. Although the amount of AA absorbed from the peritoneal cavity was small in comparison with dietary AA intake, there were significant metabolic effects. These metabolic responses are in line with other studies that reported that an increased protein supply stimulates both flux and oxidation. In contrast, in the fasting state (18), AAG dialysate did not stimulate oxidation, which agrees with studies that showed that low protein intake does not increase oxidation (23,24). Despite the increased oxidation, extra intraperitoneal AA stimulated protein synthesis significantly. Protein breakdown and net protein balance (*i.e.*, synthesis minus breakdown) did not change significantly with AA dialysate.

Table 2. Whole-body protein turnover^a

Patient	AGG						G					
	Flux ^b	Oxidation ^c	Intake	Synthesis ^d	Breakdown ^e	Net Protein Balance ^f	Flux	Oxidation	Intake	Synthesis	Breakdown	Net Protein Balance
1	2.55	0.66	0.87	1.88	1.68	0.20	2.56	0.62	0.71	1.94	1.85	0.09
2	2.60	0.62	1.14	1.98	1.46	0.52	2.40	0.54	0.89	1.86	1.51	0.35
3	3.54	0.88	1.61	2.65	1.93	0.72	3.33	0.82	1.39	2.51	1.95	0.56
4	2.98	1.07	1.50	1.91	1.48	0.42	2.95	1.00	1.33	1.95	1.61	0.34
5	2.42	0.73	1.09	1.69	1.34	0.36	2.20	0.54	0.86	1.66	1.34	0.32
6	2.24	0.62	1.02	1.61	1.22	0.39	2.21	0.55	0.88	1.66	1.33	0.33
7	2.77	0.85	1.31	1.92	1.46	0.45	2.63	0.76	1.13	1.87	1.50	0.36
8	3.58	1.34	1.81	2.23	1.76	0.47	3.30	1.18	1.63	2.12	1.67	0.46
9	3.14	0.98	1.34	2.16	1.80	0.36	2.90	0.73	1.22	2.16	1.68	0.49
10	3.08	0.94	1.38	2.14	1.70	0.44	2.59	0.75	1.21	1.84	1.37	0.47
11	3.30	1.06	1.72	2.23	1.57	0.66	2.72	0.79	1.53	1.93	1.19	0.75
12	2.66	0.80	1.21	1.86	1.45	0.41	2.31	0.54	1.07	1.77	1.24	0.53
Mean	2.90	0.88	1.33	2.02	1.57	0.45	2.67	0.74	1.16	1.94	1.52	0.42
SD	0.43	0.21	0.29	0.28	0.21	0.14	0.38	0.20	0.29	0.24	0.24	0.16

^aIndividualized data are expressed in μmol leucine/kg per min. AAG, combined amino acids plus glucose dialysis; G, glucose dialysis.

^b $P = 0.001$ for flux on AAG versus G dialysis.

^c $P < 0.001$ for oxidation on AAG versus G dialysis.

^d $P = 0.039$ for synthesis on AAG versus G dialysis.

^e $P = 0.346$ for breakdown on AAG versus G dialysis.

^f $P = 0.347$ for net protein balance (is synthesis minus breakdown) on AAG versus G dialysis.

Table 3. Serum biochemistry at baseline and at the end of dialysis^a

	Baseline AAG Dialysis	End AAG Dialysis	Baseline G Dialysis	End G Dialysis
Bicarbonate (mmol/L)	23.7 \pm 3.3	25.6 \pm 3.3 ^b	24.1 \pm 3.6	25.8 \pm 2.8 ^c
Urea (mmol/L)	22.0 \pm 7.6	21.8 \pm 6.5	20.5 \pm 7.6	20.0 \pm 6.9
Creatinine ($\mu\text{mol/L}$)	841 \pm 225	762 \pm 213 ^b	835 \pm 240	773 \pm 208 ^b
Glucose (mmol/L)	4.8 \pm 1.0	6.2 \pm 2.6 ^c	4.2 \pm 1.1	5.7 \pm 2.1 ^c
Insulin (pmol/L)	134 \pm 76	495 \pm 339 ^b	133 \pm 86	458 \pm 243 ^b
CRP (mg/L)	12.2 \pm 6.9	12.2 \pm 7.8	9.1 \pm 10.6	10.8 \pm 13.3
Plasma leucine ($\mu\text{mol/L}$)	108 \pm 17.4	198 \pm 40.8 ^b	102 \pm 10.3	172 \pm 37 ^{b,d}
Dialysate leucine ($\mu\text{mol/L}$)	ND	ND	ND	0.65 \pm 0.11
Dialysate urea (mmol/9 h)	ND	174 \pm 59.1	ND	163 \pm 61.1
Dialysate protein (g/9 h)	ND	3.9 \pm 2.9	ND	4.0 \pm 2.8

^aData are mean \pm SD. CRP, C-reactive protein; ND, not determined.

^b $P < 0.01$ and ^c $P < 0.05$ versus baseline.

^d $P < 0.01$ versus end AAG dialysis.

Retention of absorbed leucine in the splanchnic bed may have influenced the results of the net protein balance. Splanchnic extraction cannot be measured directly, and a reliable assessment is difficult. Retention of 10 to 32% of gut-absorbed dietary leucine has been reported (22,25–28). Little is known about splanchnic retention of peritoneally absorbed AA (15). We assumed a value of 25% for both orally and peritoneally absorbed AA (22). Assuming increasing values of splanchnic retention brings about that the effects of protein intake shift

from inhibition of protein breakdown to stimulation of protein synthesis.

The peritoneal absorption of leucine, calculated as the difference between the amounts in fresh and spent dialysate, ranged from 29 to 51% with a dwell time of approximately 1 h. These values are similar to those reported elsewhere (15,17). In the standard CAPD procedure with a dwell time of 4 to 6 h, AA absorption is considerably higher (15,29,30). Plasma leucine levels increased significantly with the AA dialysis fluid. The

higher plasma leucine levels as a result of feeding may have caused a slightly lower absorption rate of intraperitoneal AA as a result of a decreased gradient compared with the fasting state.

Calories have an inhibitory effect on protein breakdown *via* stimulation of insulin secretion, whereas AA may exert a separate and additive effect (31,32). In this study, the intake of calories was virtually the same during AAG and G dialysis. Intraperitoneal AA did not lead uniformly to lower protein degradation; neither was it associated with a different insulin response.

Comparing the results of this and our previous published studies (18) in similar patients, we found that protein synthesis rates were significantly higher in the fed state as compared with the fasting state with both AAG and G dialysis. The synthesis rates (mean values in μmol leucine/kg per min) using AAG dialysate were 2.02 (fed state; $n = 12$) as compared with 1.20 (fasting state; $n = 8$; $P < 0.001$) and using G only dialysate were 1.94 (fed state; $n = 12$) versus 1.10 (fasting state; $n = 8$; $P < 0.001$). Protein breakdown did not significantly differ in response to feeding between the two studies with both AAG and G dialysis. This suggests that ingested protein was used mainly for stimulation of protein synthesis. That G-containing dialysate has been found to inhibit protein breakdown in fasting patients through moderate hyperinsulinemia may explain why feeding did not inhibit proteolysis further (16). Net protein balance was negative during fasting but became positive in all patients who were taking oral food, as also has been demonstrated in healthy people and hemodialysis patients (23,33).

Giving dialysis fluid that contains a mixture of AA and G guarantees simultaneous supply of both protein and calories when oral intake of proteins and calories is deficient in anorectic CAPD patients. In this study, most patients were not malnourished according to the SGA classification.

In a subgroup analysis, we compared the results of WBPT in the four malnourished patients (SGA-B) with the eight well-nourished ones (SGA-A). In malnourished patients, the AAG dialysate showed a statistically significant increase in net protein balance compared with the G dialysate. This suggests that the nutritional state may play a role in the metabolic effects of AAG dialysis.

This study is the first to examine the metabolic effects of AA absorbed from AAG-containing dialysate on WBPT in fed CAPD patients. The results represent acute effects that were obtained in a relatively well-nourished and stable CAPD population. Further work is needed to evaluate the metabolic effects of AAG dialysate in the presence of inflammation or in malnourished patients.

Conclusion

Even in a fed state, dialysis solutions that contain AAG improve protein synthesis in CAPD patients. These solutions could function as a nutritional supplement and may help to improve the nutritional state in CAPD patients with deficient intake of both proteins and calories. For assessment of the long-term effects on nutritional status, morbidity, and mortality in different subgroups, studies in a large number of patients are needed.

Acknowledgments

This study was supported by grants from Baxter Benelux.

We thank the patients for participation and Laurens J. van Dijk, PD nurse, Adorée M. van der Wiel, dietitian, and Marja Belder, nurse, for cooperation in the study.

Disclosures

None.

References

1. Kopple JD: McCollum Award Lecture, 1996: Protein-energy malnutrition in maintenance dialysis patients. *Am J Clin Nutr* 65: 1544–1557, 1997
2. Young GA, Kopple JD, Lindholm B, Vonesh EF, De Vecchi A, Scalapogna A, Castelnova C, Oreopoulos DG, Anderson GH, Bergstrom J, DiChiro J, Gentile D, Nissenson A, Sakhrani L, Brownjohn AM, Nolph KD, Prowant BF, Algrim CE, Martis L, Serkes KD: Nutritional assessment of continuous ambulatory peritoneal dialysis patients: An international study. *Am J Kidney Dis* 17: 462–471, 1991
3. Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW: Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. *Kidney Int* 21: 849–861, 1982
4. Mitch WE, Maroni BJ: Factors causing malnutrition in patients with chronic uremia. *Am J Kidney Dis* 33: 176–179, 1999
5. Blumenkrantz MJ, Gahl GM, Kopple JD, Kamar AV, Jones MR, Kessel M, Coburn JW: Protein losses during peritoneal dialysis. *Kidney Int* 19: 593–602, 1981
6. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD: Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences. *Am J Kidney Dis* 42: 864–881, 2003
7. Pupim LB, Caglar K, Hakim RM, Shyr Y, Ikizler TA: Uremic malnutrition is a predictor of death independent of inflammatory status. *Kidney Int* 66: 2054–2060, 2004
8. Mitch WE: Insights into the abnormalities of chronic renal disease attributed to malnutrition. *J Am Soc Nephrol* 13[Suppl]: S22–S27, 2002
9. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. *Kidney Int* 55: 1899–1911, 1999
10. Bergstrom J, Lindholm B: Malnutrition, cardiac disease, and mortality: An integrated point of view. *Am J Kidney Dis* 32: 834–841, 1998
11. Bruno M, Bagnis C, Marangella M, Rovera L, Cantaluppi A, Linari F: CAPD with an amino acid dialysis solution: A long-term, cross-over study. *Kidney Int* 35: 1189–1194, 1989
12. Chertow GM, Lazarus JM, Lyden ME, Caudry D, Nordberg P, Lowrie EG: Laboratory surrogates of nutritional status after administration of intraperitoneal amino acid-based solutions in ambulatory peritoneal dialysis patients. *J Ren Nutr* 5: 116–123, 1995
13. Jones M, Hagen T, Boyle CA, Vonesh E, Hamburger R, Charytan C, Sandroni S, Bernard D, Piraino B, Schreiber M, Gehr T, Fein P, Friedlander M, Burkart J, Ross D, Zimmerman S, Swartz R, Knight Th, Kraus A, McDonald L, Hartnett M, Weaver M, Martis L, Moran J: Treatment of mal-

- nutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicenter outpatient study. *Am J Kidney Dis* 32: 761–769, 1998
14. Kopple JD, Bernard D, Messana J, Swartz R, Bergstrom J, Lindholm B, Lim V, Brunori G, Leiserowitz M, Bier DM, Stegink LD, Martis L, Boyle CA, Serkes KD, Vonesh E, Jones MR: Treatment of malnourished CAPD patients with an amino acid based dialysate. *Kidney Int* 47: 1148–1157, 1995
 15. Delarue J, Maingourd C, Objois M, Pinault M, Cohen R, Couet C, Lamisse F: Effects of an amino acid dialysate on leucine metabolism in continuous ambulatory peritoneal dialysis patients. *Kidney Int* 56: 1934–1943, 1999
 16. Garibotto G, Sofia A, Canepa A, Saffiotti S, Sacco P, Sala MR, Dertennois L, Pastorino N, Deferrari G, Russo R: Acute effects of peritoneal dialysis with dialysates containing dextrose or dextrose and amino acids on muscle protein turnover in patients with chronic renal failure. *J Am Soc Nephrol* 12: 557–567, 2001
 17. Canepa A, Carrea A, Menoni S, Verrina E, Trivelli A, Gusmano R, Perfumo F: Acute effects of simultaneous intraperitoneal infusion of glucose and amino acids. *Kidney Int* 59: 1967–1973, 2001
 18. Tjong HL, Van den Berg JW, Wattimena JL, Rietveld T, Van Dijk LJ, Van der Wiel AM, Van Egmond AM, Fieren MW, Swart R: Dialysate as food: Combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. *J Am Soc Nephrol* 16: 1486–1493, 2005
 19. Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA, Jeejeeboy KN: What is subjective global assessment of nutritional status? *J Parenter Enteral Nutr* 11: 8–13, 1987
 20. Schwenk WF, Beaufriere B, Haymond MW: Use of reciprocal pool specific activities to modal leucine metabolism in humans. *Am J Physiol* 249: E646–E650, 1985
 21. Matthews DE, Motil KJ, Rohrbaugh DK, Burke JF, Young VR, Bier DM: Measurement of leucine metabolism in man from a primed, continuous infusion of L-[1-3C]leucine. *Am J Physiol* 238: E473–E479, 1980
 22. Forslund AH, Hambraeus L, Olsson RM, El-Khoury AE, Yu YM, Young VR: The 24-h whole body leucine and urea kinetics at normal and high protein intakes with exercise in healthy adults. *Am J Physiol* 275: E310–E320, 1998
 23. Gibson NR, Fereday A, Cox M, Halliday D, Pacy PJ, Millward DJ: Influence of dietary energy and protein on leucine kinetics during feeding in healthy adults. *Am J Physiol* 270: E282–E291, 1996
 24. Pacy PJ, Price GM, Halliday D, Quevedo MR, Millward DJ: Nitrogen homeostasis in man: the diurnal responses of protein synthesis and degradation and amino acid oxidation to diets with increasing protein intakes. *Clin Sci* 86: 103–118, 1994
 25. Hoerr RA, Matthews DE, Bier DM, Young VR: Leucine kinetics from [2H3]- and [13C] leucine infused simultaneously by gut and vein. *Am J Physiol* 260: E1111–E1117, 1991
 26. Castillo L, Chapman TE, Yu YM, Ajami A, Burke JF, Young VR: Dietary arginine uptake by the splanchnic region in adult humans. *Am J Physiol* 265: E532–E539, 1993
 27. Cayol M, Boirie Y, Rambourdin F, Prugnaud J, Gachon P, Beaufriere B, Obled C: Influence of protein intake on whole body and splanchnic leucine kinetics in humans. *Am J Physiol* 272: E584–E591, 1997
 28. Goodship TH, Mitch WE, Hoerr RA, Wagner DA, Steinman TI, Young VR: Adaptation to low-protein diets in renal failure: Leucine turnover and nitrogen balance. *J Am Soc Nephrol* 1: 66–75, 1990
 29. Jones MR, Gehr TW, Burkart JM, Hamburger RJ, Kraus AP Jr, Piraino BM, Hagen T, Ogrinc FG, Wolfson M: Replacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solution. *Perit Dial Int* 18: 210–216, 1998
 30. Goodship TH, Lloyd S, McKenzie PW, Earnshaw M, Smeaton I, Bartlett K, Ward MK, Wilkinson R: Short-term studies on the use of amino acids as an osmotic agent in continuous ambulatory peritoneal dialysis. *Clin Sci* 73: 471–478, 1987
 31. Castellino P, Luzi L, Simonson DC, Haymond M, DeFronzo RA: Effect of insulin and plasma amino acid concentrations on leucine metabolism in man. Role of substrate availability on estimates of whole body protein synthesis. *J Clin Invest* 80: 1784–1793, 1987
 32. Volpi E, Lucidi P, Cruciani G, Monacchia F, Reboldi G, Brunetti P, Bolli GB, De Feo P: Contribution of amino acids and insulin to protein anabolism during meal absorption. *Diabetes* 45: 1245–1252, 1996
 33. Veeneman JM, Kingma HA, Boer TS, Stellaard F, De Jong PE, Reijngoud DJ, Huisman RM: Protein intake during hemodialysis maintains a positive whole body protein balance in chronic hemodialysis patients. *Am J Physiol Endocrinol Metab* 284: E954–E965, 2003